Pulse Biosciences, Inc. PLSE
Set alert
52.24 USD -3.24 -5.84%
At close
52.24 0.00 0.00%
Pre-market · Nov 2, 8:24 AM ET
51.39 Day range 54.70
12.56 52-week range 58.90
- YTD
- +280.48%
- 1 year
- +208.56%
- Open
- 54.33
- Prev close
- 55.48
- Mkt cap
- 3.73B
- Vol
- 466.45K
- Avg vol
- 503.42K
- EPS
- -1.18
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 51.39
- High
- 54.70
- Forward P/E
- -44.65
- Beta
- 1.57
- Short ratio
- 5.88
- Inst. own
- 15.32%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 50.99
- 200-d avg
- 31.16
- 1y target
- 62.33
1D chart
Signals (40)
| Name | Time | Ago |
|---|---|---|
| MACD: Buy Signal | 3:47 PM | 2 days ago |
| SMA: Bullish | 3:46 PM | 2 days ago |
| SMA: Bullish | 3:46 PM | 2 days ago |
| SMA: Bearish | 3:43 PM | 2 days ago |
| SMA: Bearish | 3:43 PM | 2 days ago |
| SMA: Bullish | 3:40 PM | 2 days ago |
| SMA: Bullish | 3:40 PM | 2 days ago |
| SMA: Bearish | 3:34 PM | 2 days ago |
| SMA: Bearish | 3:34 PM | 2 days ago |
| MACD: Sell Signal | 3:34 PM | 2 days ago |
| SMA: Bullish | 3:33 PM | 2 days ago |
| SMA: Bullish | 3:33 PM | 2 days ago |
| SMA: Bearish | 3:31 PM | 2 days ago |
| SMA: Bearish | 3:30 PM | 2 days ago |
| SMA: Bullish | 3:24 PM | 2 days ago |
| SMA: Bullish | 3:21 PM | 2 days ago |
| MACD: Buy Signal | 3:18 PM | 2 days ago |
| MACD: Sell Signal | 3:14 PM | 2 days ago |
| SMA: Bearish | 3:13 PM | 2 days ago |
| SMA: Bullish | 3:12 PM | 2 days ago |
| MACD: Buy Signal | 2:57 PM | 2 days ago |
| SMA: Bearish | 2:11 PM | 2 days ago |
| MACD: Sell Signal | 2:11 PM | 2 days ago |
| SMA: Bearish | 2:10 PM | 2 days ago |
| SMA: Bullish | 2:08 PM | 2 days ago |
| SMA: Bearish | 1:57 PM | 2 days ago |
| SMA: Bullish | 1:52 PM | 2 days ago |
| SMA: Bearish | 1:46 PM | 2 days ago |
| SMA: Bullish | 1:45 PM | 2 days ago |
| SMA: Bullish | 1:31 PM | 2 days ago |
| MACD: Buy Signal | 1:05 PM | 2 days ago |
| RSI: Oversold | 12:59 PM | 2 days ago |
| RSI: Oversold | 12:53 PM | 2 days ago |
| MACD: Sell Signal | 12:32 PM | 2 days ago |
| MACD: Buy Signal | 12:28 PM | 2 days ago |
| SMA: Bearish | 11:43 AM | 2 days ago |
| SMA: Bullish | 11:41 AM | 2 days ago |
| SMA: Bearish | 11:36 AM | 2 days ago |
| MACD: Sell Signal | 11:36 AM | 2 days ago |
| SMA: Bullish | 11:06 AM | 2 days ago |
Key statistics
- Market cap
- 3.73B
- Enterprise value
- 3.86B
- Trailing P/E
- 0.00
- Forward P/E
- -44.65
- PEG ratio
- 0.00
- Price / sales
- 3144.21
- Price / book
- 37.18
- EPS (TTM)
- -1.18
- Beta
- 1.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.19M
- Revenue growth
- 0.00%
- Free cash flow
- -34.29M
- Total cash
- 101.62M
- Total debt
- 6.77M
- Return on equity
- -78.49%
- Shares outstanding
- 71.32M
- Short % of float
- 14.09%
- 50-day average
- 50.99
- 200-day average
- 31.16
Analyst view
Consensus: none
Price target (mean) 62.33 +19.3% upside
Now 52.24
- Target (low)
- 55.00
- Target (mean)
- 62.33
- Target (high)
- 73.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.2875.
Financials — quick view
PLSE Revenue — quarterly 434.00K
PLSE Net income — quarterly -24.66M
PLSE EPS — quarterly -0.36
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.3095 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.31 | -0.36 | -0.05 | -16.13% |
| May 4, 2026 | Mar 31, 2026 | -0.32 | -0.27 | +0.05 | +15.62% |
| Feb 19, 2026 | Dec 31, 2025 | -0.265 | -0.26 | +0.01 | +1.89% |
| Nov 5, 2025 | Sep 30, 2025 | -0.31 | -0.29 | +0.02 | +6.45% |
| Aug 12, 2025 | Jun 30, 2025 | -0.26 | -0.28 | -0.02 | -7.69% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | Oppenheimer | main | Outperform | Outperform |
| Oct 6, 2026 | Canaccord Genuity | main | Buy | Buy |
| Sep 23, 2026 | BTIG | init | — | Buy |
| Sep 9, 2026 | Freedom Capital Markets | init | — | Buy |
| Aug 17, 2026 | Needham | init | — | Buy |
| Aug 10, 2026 | Canaccord Genuity | main | Buy | Buy |
About Pulse Biosciences, Inc.
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- pulsebiosciences.com
News
- Pulse Biosciences to Present at Stifel 2026 Healthcare Conference
- Pulse Biosciences Partners With Clayman Thyroid Center At Hospital For Endocrine Surgery In Tampa, Florida
- Oppenheimer Maintains Outperform on Pulse Biosciences, Raises Price Target to $60
- Canaccord Genuity Maintains Buy on Pulse Biosciences, Raises Price Target to $58
- TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday
- This HCA Healthcare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
- BTIG Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $70
- Pulse Biosciences Files Prospectus Supplement For Up To $85M At-The-market Common Stock Offering Via Mizuho; Terminates TD Cowen Distribution Agreement On Sept 14, 2026 With $1M Unsold
- Pulse Biosciences Concludes 100 Patient Enrollment in PRECISE-BTN Study of nPulse Vybrance Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
- Wealthfront, Orchestra Biomed, AeroVironment And Other Big Stocks Moving Higher On Thursday
Your note
Sign in to keep a note on PLSE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARRETT BURKE T | Former | Sale | Dec 10, 2024 | 63,172 |
| DANAHY KEVIN PATRICK | Officer | Conversion of Exercise of derivative security | Feb 17, 2026 | 43,298 |
| DUGGAN ROBERT WILLIAM | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | May 10, 2026 | 49,291,700 |
| LAVIOLETTE PAUL A | Chief Executive Officer | Purchase | May 10, 2026 | 15,846 |
| UECKER DARRIN R | Chief Technology Officer | Conversion of Exercise of derivative security | Sep 16, 2025 | 284,406 |
| ZANGANEH MAHKAM | Director | Conversion of Exercise of derivative security | Feb 2, 2025 | 873,469 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 2.07% | 1,466,702 | 76.62M | Jun 29, 2026 |
| Bank of America Corporation | 2.04% | 1,446,611 | 75.57M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 1.11% | 788,640 | 41.20M | Jun 29, 2026 |
| Portolan Capital Management, LLC | 1.06% | 753,333 | 39.35M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 1.06% | 748,638 | 39.11M | Jun 29, 2026 |
| Balyasny Asset Management LP | 1.01% | 718,103 | 37.51M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 0.78% | 554,612 | 28.97M | Jun 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 0.69% | 485,300 | 25.35M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 0.69% | 489,643 | 25.58M | Sep 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd. | 0.49% | 343,542 | 17.95M | Aug 30, 2026 |
| MFS SERIES TRUST I-MFS New Discovery Fund | 0.48% | 339,453 | 17.73M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.30% | 215,880 | 11.28M | Jun 29, 2026 |